More Positive Data for Tirzepatide Weight Loss Injection + Sandoz’s Global Biosimilars Awareness Campaign

In this episode, Ayesha discussed new data shared by Eli Lilly for its weight loss injection tirzepatide. The drug was recently approved (under the brand name Mounjaro) by the US Food and Drug Administration (FDA) for the treatment of type 2 diabetes. The dual GIP/GLP-1 receptor agonist also has weight loss effects and recent analyses presented at the American Diabetes Association’s 82nd Scientific Sessions showed that almost 40 percent of participants lost a quarter of their body weight. Hear more about the newest data and industry predictions for tirzepatide as a rival to Novo Nordisk’s GLP-1 receptor agonist weight loss injection Wegovy.

The editorial team also discussed a new global biosimilars awareness campaign launched by Sandoz, Novartis’ biosimilars and generics drug division. The campaign is called Act4Biosimilars and will focus on improving the acceptability and accessibility to biosimilars, among factors, by 30 percent in over 30 countries by the year 2030. The campaign is aimed at addressing global health inequity and inequality by increasing access to advanced medicines like biosimilars. The team discussed the importance of education around biosimilars to help increase their acceptability and uptake.

Read the full articles here: 

More Positive Data for Eli Lilly’s Diabetes and Weight Loss Injection Tirzepatide

Novartis’ Sandoz Launches Biosimilars Awareness Campaign to Improve Biosimilars Adoption Worldwide

For more life science and medical device content, visit the Xtalks Vitals homepage.

Follow Us on Social Media

Twitter: @Xtalks
Instagram: @Xtalks
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured